COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Myopia Progression Trial With Novel Myopia Control Design Spectacle Lenses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04048148
Recruitment Status : Recruiting
First Posted : August 7, 2019
Last Update Posted : August 12, 2019
Essilor International
Hai Yen Eye Care
Information provided by (Responsible Party):
Rebecca Weng, Brien Holden Vision Institute

Brief Summary:
This is a mono-center, randomized, double-masked, cross-over study to evaluate rate of myopia progression with novel designed myopia control lens (test) compared to SVL (control). A total of 120 children will be recruited where 60 participants each will be randomized either to wear test (Group 1) or SVL lenses (Group 2) for 6 months each. At the end of the 6 months period, there will be a cross- over of lenses and the lenses evaluated for a further 6 months.

Condition or disease Intervention/treatment Phase
Myopia Device: Novel designed myopia control spectacle lenses Not Applicable

Detailed Description:

Myopia has been considered as a 'global epidemic' owing to its rapid rise in prevalence across the world. Myopia significantly affects the quality of life of an individual socially by restriction of employment in various fields and economically by additional cost for eye care and spectacles and contact lenses (Lim, Gazzard et al. 2009). In addition, high myopia increases the risk of ocular morbidity such as retinal detachment, cataract, glaucoma which can could lead to blindness. Several optical and pharmaceutical strategies were developed over the recent years that could control or slow the progression of myopia.

It has been shown that persistent myopic defocus constantly applied on the whole retina has a beneficial effect on myopia progression, i.e. decrease in myopia progression (Anstice and Phillips 2011, Cheng, Woo et al. 2011, Ehsaei, Chisholm et al. 2011). In addition, a meta-analysis on the efficacy of non-invasive optical treatment strategies for myopia control reported prismatic bifocals to have the best outcome (Cheng, Woo et al. 2011). Therefore, test lenses were designed to increase the area and amount of myopic defocus on the retina without compromising vision.

Thus, this study aims to evaluate the efficacy of test lenses to reduce the progression of myopia by either reducing the myopia progression rate per year and/or reducing the elongation of eyeball through myopic defocus compared with SVL. A total of 120 healthy children aged 8 to 13 years will be recruited to participate in a double-masked cross-over clinical trial. Cycloplegic autorefraction will be the primary measure for myopia progression and axial length will the secondary outcome measure. Visual acuity will also be compared between test lens and control lens to determine the quality of vision using test lens.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: This is a mono-center, randomized, double-masked, cross-over study to evaluate if novel design lens can slow down the progression of myopia. A total of 120 healthy children aged between 8 years to 13 years with myopia (-0.75D to -4.75D) meeting the inclusion and exclusion criteria will be recruited. These children will be randomized to wear test lenses followed by control lenses (Group 1) or to wear control lenses followed by test lenses (Group 2). The duration of lens wear with each lens type will be 6 months. All children will be followed at 3-monthly intervals for 1 year to monitor for changes in axial length and 6-monthly for changes in cycloplegic autorefraction. The cross-over design allows to compare treatment effects between the two groups at 6 months and at 12 months. In addition, at the end of the study, the treatment effects can be compared within subject as each subject will have worn both test lenses and control lenses and serves as his/her control.
Masking: Double (Participant, Investigator)
Masking Description: Participants and their parents / guardians and investigators will be masked to their lens assignment. Test spectacles will be of similar appearance to control spectacles and will not be easily identified without specialized equipment. Test and control spectacles will be assigned a code (A or B) by the clinical coordinator and stored in a secure location.
Primary Purpose: Treatment
Official Title: A Double-masked, Randomized, Cross-over Comparative Study of Novel Myopia Control Designed Lens (Test Lens) Versus Single Vision Lens (SVL; Control)
Actual Study Start Date : May 31, 2019
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : September 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
Novel myopia control lenses
This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months
Device: Novel designed myopia control spectacle lenses
A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 6 months.

Single vision lenses
This group will be randomized to wear control lenses for 6 months followed by test lenses for 6 months
Device: Novel designed myopia control spectacle lenses
A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 6 months.

Primary Outcome Measures :
  1. Cycloplegic refraction [ Time Frame: Up to 12 months ]
    Change in myopia progression measured by cycloplegic refraction (Diopters) using Shin Nippon Auto-refractor

Secondary Outcome Measures :
  1. Axial length [ Time Frame: Up to 12 months ]
    Change in ocular axial length (mm) measured using Lenstar Optical Biometer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 13 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

General inclusion criterion:

- Volunteer subject and guardian, fluent Vietnamese spoken, willing to follow the protocol and able to read, comprehend and sign the informed consent form.

Study related inclusion criteria:

  • Age: equal to or greater than 8 years and not older than 13 years.
  • Spherical refractive error of -0.75 to -4.75 D in each eye (spherical equivalent), as measured by cycloplegic autorefraction.
  • Astigmatism of not more than 1.50 D.
  • Anisometropia of not more than 1.00 D.
  • Best corrected visual acuity of equal or better than 0.05 LogMAR
  • No strabismus by cover test at near and distance.
  • Have the ability to comply with the protocol to get the reliable study measurements.
  • Absence of ocular disease with full ophthalmic examination, such as retinal disease, cataract and ptosis. Good general health, without systemic or neurodevelopmental conditions. Without ocular or systemic medicine, which might affect myopia progression or visual acuity through known effects on retina, accommodation or significant elevation of intraocular pressure.
  • No history of progressive addition lenses (PALs) or bifocal use and no prior use of contact lenses

Exclusion Criteria:

General exclusion criteria:

  • Vulnerability of the subject,
  • Participation in another study which might have an influence on vision or interfere with study assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04048148

Layout table for location contacts
Contact: Rebecca Weng, GD +61293857465
Contact: Huy Tran, MD +84907110892

Layout table for location information
Hai Yen Eye Care Recruiting
Ho Chi Minh City, Vietnam, 700000
Contact: Huy Tran, MD    +84907110892   
Contact: Anh Pham, MA    +61420780206   
Sponsors and Collaborators
Brien Holden Vision Institute
Essilor International
Hai Yen Eye Care
Layout table for investigator information
Study Director: Padmaja Sankaridurg, PhD Brien Holden Vision Institute
Layout table for additonal information
Responsible Party: Rebecca Weng, Senior Project Manager, Brien Holden Vision Institute Identifier: NCT04048148    
Other Study ID Numbers: VCRTC2019-01
First Posted: August 7, 2019    Key Record Dates
Last Update Posted: August 12, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Clinical study report will be shared once the study is completed. Study anticipate to be completed in 2020.
Supporting Materials: Clinical Study Report (CSR)
Time Frame: The data will become available mid 2021, starting 6 months after publication.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases